Prepared by:
Oregon Health & Science University
Oregon Evidence-based Practice Center
Portland, OR 97239
Roger Chou, M.D.
Elizabeth Clark, M.D., M.P.H.
Mark Helfand, M.D., M.S.
File Name Description Software Version File Size _____________________________________________________________________________________________________ 01rept.doc Microsoft Word® Document MS Word® 2002 788KB 83 pages Contents: Cover, Title Page, Preface, Abstract, Table of Contents; Chapter 1. Introduction: Published Guidelines, Burden of Suffering, Definitions, Natural History, Analytic Framework and Key Questions; Chapter 2. Methods: Search Strategy, Inclusion Criteria, Data Extraction; Chapter 3. Results: Arrow 1: Does screening for hepatitis C reduce the risk or rate of harm and premature death and disability?, Arrow 2: Can clinical or demographic characteristics identify a subgroup of asymptomatic patients at higher risk for HCV infection?, Arrow 3: What are the test characteristics of HCV antibody testing?, Arrow 4: What is the false-positive rate and what are the harms associated with screening for hepatitis C virus?, Arrow 5a: What are the test characteristics off the work-up for treatable disease?, Arrow 5b: In patients found to be positive for hepatitis C antibody, what proportion of patients would qualify for antiviral treatment?, Arrow 6: What are the harms associated with the work-up for active HCV disease?, Arrow 7a: How well does antiviral treatment reduce the rate of viremia, improve transaminase levels, and improve histology?, Arrow 7b: How well does antiviral treatment improve health outcomes in asymptomatic patients with hepatitis C?, Arrow 7c: How well do counseling and immunizations in asymptomatic patients with hepatitis C improve clinical outcomes or prevent spread of disease?, Arrow 8: What are the harms (including intolerance to treatment) associated with antiviral treatment?, Arrow 9: Have improvements in intermediate outcomes (liver function tests, viral remission, histologic changes) been shown to reduce the risk or rate of harm from hepatitis C?; Conclusions; Future Research Priorities; References _____________________________________________________________________________________________________ 02tbl1.xls Microsoft Excel® Worksheet MS Excel® 2002 12KB 1 page Contents: Table 1. Current HCV Screening Recommendations _____________________________________________________________________________________________________ 03tbl2.xls Microsoft Excel® Worksheet MS Excel® 2002 9KB 1 page Contents: Table 2. HCV Screening Test Results and Usual Interpretation _____________________________________________________________________________________________________ 04tbl3.xls Microsoft Excel® Worksheet MS Excel® 2002 10KB 1 page Contents: Table 3. Long-term Outcomes of Chronic HCV Infection in Community-based Cohorts Including Asymptomatic Patients _____________________________________________________________________________________________________ 05tbl4.xls Microsoft Excel® Worksheet MS Excel® 2002 14KB 3 pages Contents: Table 4. Independent Risk Factors for HCV Infection from Large Observational Studies _____________________________________________________________________________________________________ 06tbl5.xls Microsoft Excel® Worksheet MS Excel® 2002 9KB 1 page Contents: Table 5. Comparative Treatment Response Rates for HCV Infection _____________________________________________________________________________________________________ 07tbl6.xls Microsoft Excel® Worksheet MS Excel® 2002 18KB 1 page Contents: Table 6. Differences Between Responders and Non-responders in Baseline and 24 Week SF-36 Scores _____________________________________________________________________________________________________ 08tbl7.xls Microsoft Excel® Worksheet MS Excel® 2002 23KB 4 pages Contents: Table 7. Summary of Findings of Systematic Review _____________________________________________________________________________________________________ 09tbl8.xls Microsoft Excel® Worksheet MS Excel® 2002 12KB 2 pages Contents: Table 8. Estimated Yield of Screening for Hepatitis C Virus _____________________________________________________________________________________________________ 10etbl1a.xls Microsoft Excel® Worksheet MS Excel® 2002 76KB 12 pages Contents: Evidence Table 1a. Intermediate Outcomes _____________________________________________________________________________________________________ 11etbl1b.xls Microsoft Excel® Worksheet MS Excel® 2002 30KB 2 pages Contents: Evidence Table 1b. Quality of RCTs for Treatment-Intermediate Outcomes _____________________________________________________________________________________________________ 12etbl2.xls Microsoft Excel® Worksheet MS Excel® 2002 36KB 4 pages Contents: Evidence Table 2. Interferon Plus Ribavirin Intermediate Outcomes _____________________________________________________________________________________________________ 13etbl3a.xls Microsoft Excel® Worksheet MS Excel® 2002 39KB 3 pages Contents: Evidence Table 3a. Long-term Outcomes _____________________________________________________________________________________________________ 14etbl3b.xls Microsoft Excel® Worksheet M S Excel® 2002 24KB 2 pages Contents: Evidence Table 3b. Quality of RCTs for Long-Term Outcomes _____________________________________________________________________________________________________ 15etbl4.xls Microsoft Excel® Worksheet MS Excel® 2002 20KB 2 pages Contents: Evidence Table 4. Quality of Life _____________________________________________________________________________________________________ 16fig1.ppt Microsoft PowerPoint® Presentation MS PowerPoint® 2002 54KB 1 page Contents: Figure 1. Screening for Hepatitis C: Analytic Framework and Key Questions _____________________________________________________________________________________________________
Current as of March 2004
Internet Citation:
Screening for Hepatitis C Virus Infection. File Inventory, Systematic Evidence Review Number 24. March 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/prev/hepcinv.htm.
Return to Preventive Services Files Download
U.S. Preventive Services Task Force
Clinical Information
AHRQ Home Page
Department of Health and Human Services